GlassScriptPhysician profile
John A Rescigno
NPI 1215939715
$19,968.18
in general payments reported to CMS, 2019-2025
76 companies · $4,545 in 2025
The $4,545 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $1,048 · 2021: $1,317 · 2022: $2,502 · 2023: $3,106 · 2024: $4,764 · 2025: $4,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,255.55 |
| Education | $160.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,260.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,024.66 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $1,245.60 | 2022-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $718.87 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $702.77 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $671.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $624.45 | 2019-2025 | |
| Ucb, INC. | $605.43 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
| Allergan, INC. | $558.80 | 2019-2022 | |
| Mdd US Operations, LLC | $490.32 | 2019-2025 | Apokyn, Gocovri, Apokyn |
| Genentech USA, INC. | $458.97 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $447.05 | 2019-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $417.16 | 2019-2025 | Nuplazid, Daybue |
| Ipsen Biopharmaceuticals, INC | $385.20 | 2019-2025 | Dysport |
| Ge Healthcare | $360.04 | 2019-2025 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rescigno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.